Whole body glucose metabolism and insulin secretion in KO mice. by Yasutaka Miyachi (3178986)

Evaluation of developmental toxicity and teratogenicity. by Shen Huang (9967526)

RICTOR silencing inhibits cell proliferation via UGCG regulation. by Mohammad Nafees Ansari (22232505)

“…(<b>F</b>) Fold change (mean ± SEM, <i>n</i> = 5) in different sphingolipid species reveals an increase in ceramides and a decrease in glucosylceramides in MCF-7_RICTOR^SH cells compared to MCF-7 cells. …”

DNA double strand break levels increase with age in <i>fog-2</i> feminized germlines. by Erik Toraason (5724689)

Fig 3 - by Sara Hintze (3216885)

Effects of bortezomib on total OATP1B1 and OATP1 B3 protein levels and total ubiquitin-conjugated proteins in human SCH. by Khondoker Alam (1443499)

Total lipid contents of ovaries from queens sampled at different seasonal time points. by Mark J. Carroll (3605582)

Percentage of living PC3 cells in presence of DRS-B2 and sodium chlorate. by Célia Dos Santos (306471)

Effects of lysosome inhibitor chloroquine on total protein levels of OATP1B3 in HEK293-OATP1B3 cells and human SCH. by Khondoker Alam (1443499)

Synthesis and characterization of dendrimer-cysteamine nano-formulation. by Scott Mackenzie Brockman (4433614)

Effect of cGAS deficiency on picornaviruses replication <i>in vitro</i>. by Huisheng Liu (408091)

Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

“…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”

Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

“…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”

Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

“…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”

Receiver position and time error applying range difference method. by Jae Hwan Bong (17054738)

Transition matrix of LULC change (ha) between 1999 and 2009. by Ajit Kumar Rudra (21647706)

Fluorescence time-lapse imaging of a single GPR3-HT-expressing CGN. by Tatsuhiro Miyagi (847543)

“…<p>(A-B) The CGNs were transfected with the pGPR3-HT expression vector and were plated onto 0.03% PEI-coated plates. …”

(A) Effect of calcium chelators and K channel antagonist, ChTX on fEPSP during OGD. by Shirin Jalini (2551054)

“…<b>(</b>B) Effect of calcium chelators, and BK channel antagonist on recovery of fEPSP after OGD. BAPTA-AM (1 μM) decreases recovery time from 2 min (n = 7), 4 min (n = 6) and 6 min (n = 3) of <i>in vitro</i> OGD compared to control (n = 7, 5, 5, respectively). …”

Cardiac hypertrophy in mice with cardiac deletion of <i>Prdm16</i>. by Ji-One Kang (844616)

Effects of Acute Systemic Hypoxia and Hypercapnia on Brain Damage in a Rat Model of Hypoxia-Ischemia by Wanchao Yang (3373424)

“…<div><p>Therapeutic hypercapnia has the potential for neuroprotection after global cerebral ischemia. Here we further investigated the effects of different degrees of acute systemic hypoxia in combination with hypercapnia on brain damage in a rat model of hypoxia and ischemia. …”